Fig. 7: Association of THEMIS2 expression levels with clinical outcomes in patients with breast cancer. | Oncogene

Fig. 7: Association of THEMIS2 expression levels with clinical outcomes in patients with breast cancer.

From: Novel function of THEMIS2 in the enhancement of cancer stemness and chemoresistance by releasing PTP1B from MET

Fig. 7

A THEMIS2 protein levels in 465 pairs of breast cancer tissues and their adjacent normal tissues were examined using IHC staining (***P < 0.001). B THEMIS2 protein levels were correlated with overall survival in all 465 patients. Kaplan–Meier analysis of Oncolink (https://www.oncolink.org/cancers/breast) (C) and Oncomine database (TCGA Breast and TCGA Breast 2, https://www.oncomine.org/resource/login.html) (D) for TNBC revealed that patients with high expression of THEMIS2 had worse overall survival compared to the THEMIS2 low expression patients. E The THEMIS2 protein levels were determined using IHC staining in a commercial tissue array slide containing 136 TNBC specimens. Representative images of tissue from patients with stages I, II, and III cancer are presented. The floating column chart represents means ± SEs from three independent experiments (***P < 0.001). F THEMIS2 and p-MET protein levels in the 465 specimens were positively correlated. G The proposed model of high level THEMIS2 may sensitize CPT and Capmatinib in TNBC. In brief, THEMIS2 enhances cancer stemness, chemoresistance and tumorigenicity by suppressing p-MET–PTP1B interaction to activate MET phosphorylation.

Back to article page